Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67,570 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Dang NH, et al. Among authors: wang m. J Clin Oncol. 2004 Oct 15;22(20):4095-102. doi: 10.1200/JCO.2004.03.071. Epub 2004 Sep 7. J Clin Oncol. 2004. PMID: 15353540 Clinical Trial.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Goy A, et al. Among authors: wang m. J Clin Oncol. 2005 Feb 1;23(4):667-75. doi: 10.1200/JCO.2005.03.108. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613697 Clinical Trial.
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. Romaguera JE, et al. Among authors: wang m. J Clin Oncol. 2005 Oct 1;23(28):7013-23. doi: 10.1200/JCO.2005.01.1825. Epub 2005 Sep 6. J Clin Oncol. 2005. PMID: 16145068 Clinical Trial.
Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Wang M, et al. Expert Rev Anticancer Ther. 2006 Jul;6(7):983-91. doi: 10.1586/14737140.6.7.983. Expert Rev Anticancer Ther. 2006. PMID: 16831071 Review.
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB. Safdar A, et al. Among authors: wang m. J Infect Dis. 2006 Nov 15;194(10):1394-7. doi: 10.1086/508493. Epub 2006 Oct 6. J Infect Dis. 2006. PMID: 17054068 Clinical Trial.
67,570 results
You have reached the last available page of results. Please see the User Guide for more information.